virus (EBV) is a widespread γ-herpesvirus with tendency to B lymphocytes which can set up an asymptomatic infection for a life time. It is widely spread and infects more than 90% of the population worldwide.
Occasionally, PTLD may manifest as EBV-positive mucocutaneous ulcer (MCU). 8, 9 When it comes to pathological manifestations, progressive increasing of EBV-DNA copies in peripheral blood and lactate dehydrogenase (LDH) levels in serum even multiorgan dysfunction could prompt the occurrence and progression of PTLD. 10 According to the 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms, PTLD can be pathologically classified as: plasmacytic hyperplasia PTLD, infectious mononucleosis PTLD, florid follicular hyperplasia PTLD, polymorphic PTLD, monomorphic PTLD (B-and T/NK-cell types), and classic Hodgkin lymphoma PTLD. 11 All of the types are relevant to EBV, but the disparity of prognosis among various pathological categories has not been determined yet. 12 There should be at least 2 of the following histological conditions to establish the diagnosis of EBV-PTLD: (a) a lymphoproliferative process to disrupt underlying cellular architecture, (b) existence of monoclonal or oligoclonal cell populations viral markers, and (c) EBV infection: detection of specific nucleic acid or protein in many cells. 11 Significantly, EBV nucleic acid in blood is not adequate for the diagnosis of EBV-related PTLD. 13 
| IMPAC T FAC TOR S
Recently, Uhlin et al 14 reported the increasing incidence of EBV-PTLD from <2% before 1998 to more than 6% after 2011, and the overall incidence is 4%. However, it could rise to 10-20% in patients with identified risk factors. Initial studies have shown many risk factors for EBV reactivation and EBV-PTLD for recipients after HSCT (Table 1) . Landgren et al 15 analyzed 26 901 recipients after allo-HSCT in 271 centers worldwide, and identified following major risk factors including: (a) T-cell depletion using selective methods; (b) ATG therapy to prevent or treat acute GVHD; (c) URD/HLA-mismatched donors accompanied by selective T-cell depletion or ATG therapy;
and (d) age 50 years or older at transplantation. Furthermore, they found the cumulative incidence of EBV-PTLD among recipients with one, two, more than two or without major risk factors mentioned above were 1.1%, 3.6%, 8.1%, or 0.2%, respectively.
| Reduced intensity conditioning (RIC)
The use of RIC could decrease conditioning toxicity and early mortality following HSCT. However, the enhanced immunosuppression of RIC leads to delayed reconstitution of EBV-specific immunity following HSCT and finally results in a higher incidence of EBV viremia and PTLD. 16 Several studies 17, 18 suggested that T-cell reconstitution might be delayed after RIC regimens compared to established myeloablative conditioning (MAC). Chakrabarti et al 17 compared EBVspecific cytotoxic T-cell reconstitution between recipients after RIC and MAC and found that the EBV-specific immune response was detectable only in 1/9 patients at 6 months and 7/10 patients at 1 year in RIC group, while 6/9 patients at 6 months and all patients at 1 year in MAC group. 
| HLA-mismatched and unrelated donor

| Umbilical cord blood transplantation (UCBT)
In light of some relatively large-scale studies, 20, 21 UCBT was correlated with high incidence of EBV events, especially EBV-PTLD. 
| GVHD
GVHD is a common complication following HSCT which may impair specific immune reconstruction due to the pro-inflammatory cytokine storm. 3 Thus, GVHD is also reported as a risk factor for EBV viremia and PTLD. Not only the constant antigen stimulation occurred in GVHD but also the profound immunosuppressive treatment could probably contribute the increased risk. 
. Risk factors for EB viremia and EBV-PTLD
Risk factors Main findings References
RIC T-cell reconstitution might be delayed after RIC [16] [17] [18] HLA-Mismatched and Unrelated Donor
The incidence of EBV-PTLD with haplo-identical donor was significantly higher [19] 2+ HLA antigen-mismatched related or unrelated donor had significant higher risks [15] UCBT UCBT could increase the risk of EBV events and EBV-PTLD probably due to the condition and immunosuppression [20, 21] EBV-DNA Load Both high and very low level of EBV-DNA load had a higher OS than patients with moderate intermediate EBV-DNA load [23] The very low level of EBV load was indicated as a predictive biomaker of a poor survival [24] GVHD Acute GVHD grades II-IV had a significantly higher risk for EBV viremia [25] Acute GVHD grades III-IV was a risk factor of EBV viremia [26] Both acute and chronic GVHD increased the risk of PTLD [15] Acute GVHD impairs specific immune reconstruction due to pro-inflammatory cytokine storm [3] Constant antigen stimulation occurred in GVHD and profound immunosuppressive treatment could probably contribute the risk for PTLD [14] CMV CMV reactivation reflected recovery speed of immune system in pediatric recipients after HSCT [29] CMV has been confirmed as a risk factor after both solid organ transplantation and HSCT [30] [31] [32] 34] CMV reactivation is strongly connected with EBV reactivation [33] Splenectomy Splenectomy was a risk factor [14, 35] CD5+ B cell rely on spleen, its immune regulatory function would be impaired after splenectomy, leading to EBV load explosive growth [14, 37] TCD There is a dichotomy of PTLD incidence between patients with or without TCD (≥10% vs <1%) [24, [38] [39] [40] [41] [42] Recipients with grafts T-cell depletion highly predicted EBV-PTLD [43, 44] The selective T-cell depletion had a strong association with risks higher than other TCD methods [15] Alemtuzu mab Alemtuzumab increased virus infections [17] Alemtuzumab was a risk factor for the arising of PTLD [45] The incidence of EBV-PTLD after HSCT was low in recipients with alemtuzumab [46, 47] ATG ATG use is a risk factor for PTLD [14, 15] Age Age < 20 [50] Age ≥ 50 [15] Essential Disease Patients with SAA had a higher incidence of EBV reactivation [51, 52] The diagnosis of NHL made a significant reduction in incidence of EBV reactivation and PTLD [45, 33] Other Factors CD4+ T-lymphocyte counts at day +30 > 50/μL made a decreasing risk of high-load EBV-DNA [51] TBI [53] ATG, antithymocyte globulin; CMV, cytomegalovirus; NHL, non-Hodgkin lymphoma; OS, shorter overall survival; RIC, reduced intensity conditioning; SAA, severe aplastic anemia; TBI, total body irradiation; TCD, T-cell depletion; UCBT, umbilical cord blood transplantation.
respectively), and the risk progressively increased while severity of GVHD increased.
| Cytomegalovirus (CMV)
Because of immunosuppression and leukocytopenia post-HSCT, recipients can be easily infected by bacteria, fungi and virus. 27, 28 CMV infection is a conspicuous problem as it is connected with a series of complications such as cytopenia, GVHD as well as EBV reactivation. Malgorzata et al 29 proved that CMV reactivation reflected the recovery speed of immune system in pediatric recipients after HSCT.
Currently CMV has been confirmed as a risk factor for the arising of PTLD in recipients after both solid organ transplantation and HSCT. [30] [31] [32] Francesco et al 33 detected 49 CMV reactivated cases in 101 HSCT recipients, among whom 22 patients (45%) developed EBV co-reactivation. In multivariate analysis, the authors found that CMV reactivation was the most significant factor to predict EBV reactivation and PTLD development. Bao et al 34 retrospectively
analyzed 736 recipients after allo-HSCT from January 2012 to July 2014 in a single center. CMV reactivation occurred in 310 patients, of whom the incidence of EBV infection was 32.3%. To the contrary, the incidence of EBV infection in patients without CMV reactivation was only 19.0% (P < 0.001). They concluded CMV reactivation was an independent risk factor for EBV infection by both univariate analysis and multivariate analysis.
| Splenectomy
Uhlin et al 14 reported that 12.5% (5/40) cases had a history of splenectomy in recipients with PTLD, compared to 2% (22/981) in recipients without PTLD. Furthermore, splenectomy was confirmed as an independent risk factor by both univariate analysis (P < 0.001) and multivariate analysis (hazard ratio = 4.81, 95%CI = 1.51-15.4
(P = 0.008), which was in accordance with Sundin M's study. 35 The spleen is a significant part of immune system which responsible for not only T-cell immunity but also some B-cell immunity and immunoglobulin for EBV defense probably. 36, 37 It has been reported that the splenectomy might impair the function of CD5+ B cell and then led to EBV load explosive growth. 
| T-cell depletion (TCD)
T-cell depletion (both ex vivo and in vivo) is widely used for GVHD prophylaxis and engraftment promotion, but it also has been proved as a risk factor for EBV viremia and PTLD. According to published studies, there is a dichotomy of PTLD incidence between patients with or without TCD (≥ 10% versus <1%).
24,38-42
| TCD ex vivo
Previous studies 43, 44 showed that EBV-DNA load increased in recipients receiving TCD grafts, which highly predicted EBV-PTLD.
Landgren et al 15 
| Alemtuzumab
Chakrabarti et al 17 observed a group of recipients used alemtuzumab (Campath) in vivo, and indicated that alemtuzumab used in vivo under non-myeloablative conditioning might lead to the profound delay in EBV-specific CTL reconstitution and then increased virus infections. Additionally, Burns et al reported that alemtuzumab was a risk factor for the arising of PTLD clinically. 45 , Nevertheless, there were also studies reported low incidence of EBV-PTLD in recipients with alemtuzumab, probably because alemtuzumab can also decrease B cells (the EBV reservoir).
46,47
| Antithymocyte globulin (ATG)
Landgren et al 15 observed 2269 recipients used ATG to prevent or treat acute GVHD before allo-HSCT, 39 of them developed PTLD.
The RR of PTLD by ATG therapy was 3.8(95%CI = 2.5-5.8); thus, both the ATG prophylaxis and treatment were independent factors for PTLD. Uhlin et al 14 analyzed 1021 patients from a retrospective cohort and found all the 40 PTLD patients received ATG, and no PTLD occurred in patients without ATG. They identified ATG use was a significant risk factor with statistical significance.
| Age
It is speculated that the occurrence of EBV-related B-cell lymphoproliferative disorders is associated with age because of depression of immune system with aging. 48 Meanwhile, researchers indicated that allogeneic HCT recipients with grafts T-cell depletion 50 years or older had a comparatively delayed immune reconstitution compared to younger patients. 49 Landgren et al 15 elevated age ≥ 50 as a risk factor in multi-center study, and the risk of PTLD was fivefold compared to younger patients. On the other hand, Cao et al investigated 129 patients received allo-HSCT and found age < 20 was a risk factor for EBV reactivation. 
| Essential disease
Patients affected from severe aplastic anemia (SAA) had a dramatic higher incidence of EBV reactivation along with higher viral load, because of the immunosuppressive therapy pre-HSCT which usually compromised of the use of ATG and cyclosporine. 51, 52 To the contrast, Burns et al 45 found that the non-Hodgkin lymphoma (NHL) patients had a significantly decreased incidence of EBV reactivation and PTLD (HR = 0.10, CI 0.03-0.33; P = 0.0001), which probably attributed to previous exposure of rituximab for CD20-positive cases.
Only 3 of 29 NHL patients were observed for EBV qPCR positivity, and none of them exhibited high-level EBV reactivation during the first 2 years after HSCT. In both univariate and multivariate analyses, they confirmed that NHL made a high reduction in the risk of EBV reactivation, which was consistent with the previous study by Savani et al 33 
| Other factors
Patriarca et al 51 reported that higher CD4+ T-lymphocyte counts at day +30 (>50/μL) made a sense of a decreasing risk of high-load EBV-DNA (>10 000 copies/mL), and thereafter reduced the risk of PTLD. Total body irradiation is also one of the published risk factors.
Multivariate analysis showed TBI was independently associated with higher EBV-DNA load level. 53 
| MONITORING AND INTERVENTION
Pre-emptive therapy means treatment strategies for patients after HSCT with evidence of EBV reactivation but asymptomatic EBV viremia. When it comes to the detection of EBV, it is controversial on the choice of optimal clinical specimen between whole blood (WB) and peripheral blood mononuclear cells (PBMCs) for patients following HSCT, [54] [55] [56] [57] although there might be a correlation between the two specimens (r = 0.755, P < 0.001). 58 According to recent data, detection with PBMCs seems more sensitive, but technically more complicate and not specific enough for indicating the PTLD onset when compared to WB samples. Hence, it would be more appropriate to use WB samples for monitoring EBV-DNA load. [58] [59] [60] In order to monitor EBV infection and predict PTLD arising early, quantitative real-time polymerase chain reaction (qPCR)
should be carried out to analyze WB samples for all recipients after allo-HSCT. 58 Rituximab is the most recommended agent for patients to prevent the occurrence of PTLD. However, pre-emptive rituximab therapy threshold remained to be defined, and the benefit of long-term survival was certified only in patients with very high load as 50 000 cp/mL. Apart from it, other groups of researchers suggested the threshold to receive rituximab is when the EBV viral load ≥ 1000 cp/mL on two consecutive occasions or one over 10 000 cp/mL in plasma in high-risk recipients (with unrelated or mismatched related donor or underwent RIC) or exceeding 40 000 cp/mL in WB. 41, [64] [65] [66] Besides, the progressive increase of EBV-DNA load and exacerbation of clinical manifestations should also be considered as triggers of pre-emptive treatment. 67 Additionally, a comprehensive assessment on the risk of EBV viremia and PTLD should be taken in consideration.
It is worth noting that the use of rituximab may potentially increase risk of infectious complication particularly for viral infection such as HBV. 68 
| CON CLUS ION
In spite of a series of risk factors, an available prediction model for PTLD is still absent. Furthermore, the standardization of EBV-DNA load detection methods and the criteria of pre-emptive treatment are urgent to be determined. In addition, the new therapeutics including EBV-specific CTL warrants further validation and clinical translation.
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